Jamal Tarazi

5.3k total citations · 3 hit papers
65 papers, 2.6k citations indexed

About

Jamal Tarazi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jamal Tarazi has authored 65 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Jamal Tarazi's work include Renal cell carcinoma treatment (43 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (17 papers). Jamal Tarazi is often cited by papers focused on Renal cell carcinoma treatment (43 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (17 papers). Jamal Tarazi collaborates with scholars based in United States, France and Italy. Jamal Tarazi's co-authors include Brad Rosbrook, Brian I. Rini, Sinil Kim, Robert J. Motzer, Bernard Escudier, Walter M. Stadler, Janice P. Dutcher, Thomas E. Hutson, George Wilding and Piotr Tomczak and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Jamal Tarazi

64 papers receiving 2.5k citations

Hit Papers

Axitinib versus sorafenib as second-line treatment for ad... 2013 2026 2017 2021 2013 2018 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
  2. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. profile →
  3. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
    2023 114 citations Stephen J. Freedland, Murilo Luz et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jamal Tarazi United States 24 2.0k 1.4k 1.0k 960 168 65 2.6k
Lauren McCann United States 14 2.5k 1.3× 1.9k 1.4× 1.1k 1.0× 1.3k 1.3× 243 1.4× 30 3.1k
Juan José Zarbá Argentina 7 2.0k 1.0× 1.5k 1.1× 953 0.9× 969 1.0× 193 1.1× 13 2.9k
Alexander Kavina Austria 6 1.6k 0.8× 1.2k 0.9× 689 0.7× 775 0.8× 143 0.9× 8 2.3k
Chen Mei China 14 2.2k 1.1× 1.6k 1.1× 1.2k 1.1× 1.0k 1.1× 189 1.1× 62 3.0k
Xun Lin United States 23 1.4k 0.7× 823 0.6× 943 0.9× 617 0.6× 96 0.6× 94 2.2k
N. Moore Switzerland 16 2.6k 1.3× 1.7k 1.2× 2.0k 1.9× 1.2k 1.3× 119 0.7× 27 4.0k
Oleg Gladkov Russia 18 2.3k 1.2× 1.8k 1.3× 1.8k 1.7× 1.1k 1.2× 198 1.2× 65 3.7k
Janice Dutcher United States 9 2.6k 1.3× 2.4k 1.7× 1.1k 1.0× 1.4k 1.4× 141 0.8× 13 3.6k
Sibyl Anderson United States 19 1.2k 0.6× 944 0.7× 695 0.7× 524 0.5× 81 0.5× 40 2.1k
Pamela Salman Chile 11 2.7k 1.4× 1.6k 1.1× 1.5k 1.4× 1.1k 1.1× 198 1.2× 22 3.4k

Countries citing papers authored by Jamal Tarazi

Since Specialization
Citations

This map shows the geographic impact of Jamal Tarazi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamal Tarazi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamal Tarazi more than expected).

Fields of papers citing papers by Jamal Tarazi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamal Tarazi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamal Tarazi. The network helps show where Jamal Tarazi may publish in the future.

Co-authorship network of co-authors of Jamal Tarazi

This figure shows the co-authorship network connecting the top 25 collaborators of Jamal Tarazi. A scholar is included among the top collaborators of Jamal Tarazi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamal Tarazi. Jamal Tarazi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giorgi, Ugo De, Stephen J. Freedland, Antti Rannikko, et al.. (2025). Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. Prostate Cancer and Prostatic Diseases. 29(1). 198–201. 1 indexed citations
2.
Freedland, Stephen J., Paul Sieber, Martin Gleave, et al.. (2024). Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.. Journal of Clinical Oncology. 42(4_suppl). 156–156.
3.
Shore, Neal D., Murilo Luz, Ugo De Giorgi, et al.. (2023). LBA02-09 EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE OR PLACEBO PLUS LEUPROLIDE ACETATE AND ENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER. The Journal of Urology. 209(Supplement 4). 6 indexed citations
4.
Freedland, Stephen J., Murilo Luz, Ugo De Giorgi, et al.. (2023). Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 389(16). 1453–1465. 114 indexed citations breakdown →
5.
Martini, Jean-François, Elizabeth R. Plimack, Toni K. Choueiri, et al.. (2020). Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 26(21). 5598–5608. 16 indexed citations
6.
Bracarda, Sergio, Aristotelis Bamias, Jochen Casper, et al.. (2019). Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. Clinical Genitourinary Cancer. 17(3). e689–e703. 11 indexed citations
7.
Patel, Sandip Pravin, Nathan A. Pennell, Suchita Pakkala, et al.. (2016). Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449. 2 indexed citations
8.
Atkins, M.B., Elizabeth R. Plimack, Igor Puzanov, et al.. (2016). Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. Annals of Oncology. 27. vi266–vi266. 26 indexed citations
9.
Rini, Brian I., Bernard Escudier, Hariharan Subramanian, et al.. (2015). Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 13(6). 540–547.e7. 23 indexed citations
10.
Qin, Shukui, Feng Bi, Jie Jin, et al.. (2015). Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. OncoTargets and Therapy. 8. 1363–1363. 18 indexed citations
11.
Rini, Brian I., David I. Quinn, Michael Baum, et al.. (2014). Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Targeted Oncology. 10(1). 45–53. 43 indexed citations
12.
Escudier, Bernard, M. Dror Michaelson, Robert J. Motzer, et al.. (2014). Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British Journal of Cancer. 110(12). 2821–2828. 79 indexed citations
13.
Ueda, Takeshi, Hirotsugu Uemura, Tadashi Tsukamoto, et al.. (2013). Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial. Japanese Journal of Clinical Oncology. 43(6). 616–628. 67 indexed citations
14.
Uemura, Hiroji, Ho Yeong Lim, Yoshihiko Tomita, et al.. (2012). Phase III AXIS Trial of Axitinib Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma: Asian Subgroup Analysis. Annals of Oncology. 23. xi6–xi6. 2 indexed citations
15.
Martin, Lainie P., Mark Kozloff, Roy S. Herbst, et al.. (2012). Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 107(8). 1268–1276. 21 indexed citations
16.
Trask, Peter C., Andrew G. Bushmakin, Joseph C. Cappelleri, et al.. (2011). Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. Journal of Cancer Survivorship. 5(3). 255–262. 5 indexed citations
17.
Rini, Brian I., Joan H. Schiller, John P. Fruehauf, et al.. (2011). Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. Clinical Cancer Research. 17(11). 3841–3849. 151 indexed citations
18.
Bushmakin, AG, J.C. Cappelleri, Jamal Tarazi, et al.. (2010). Can patient-reported kidney cancer–specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?. Journal of Clinical Oncology. 28(15_suppl). 6136–6136. 1 indexed citations
19.
20.
Cohen, Roger B., Mark Kozloff, Yazdi K. Pithavala, et al.. (2007). Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors. Molecular Cancer Therapeutics. 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lauren McCann Breakdown of academic impact, for papers by Juan José Zarbá Breakdown of academic impact, for papers by Alexander Kavina Breakdown of academic impact, for papers by Chen Mei Breakdown of academic impact, for papers by Xun Lin Breakdown of academic impact, for papers by N. Moore Breakdown of academic impact, for papers by Oleg Gladkov Breakdown of academic impact, for papers by Janice Dutcher Breakdown of academic impact, for papers by Sibyl Anderson Breakdown of academic impact, for papers by Pamela Salman
Rankless by CCL
2026